Amgen Reports Fourth Quarter And Full Year 2018 Financial Results

THOUSAND OAKS, Calif., Jan. 29, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2018 in comparison to comparable periods in 2017. Key results include: For the fourth quarter, total revenues increased 7 percent to $6.2 billion. Product sales grew 8 percent globally. New and recently launched products including Repatha® (evolocumab), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab) showed double-digit growth. For the full year, total revenues increased 4 percent to $23.7 billion, with 3 percent product sales growth. GAAP earnings per share (EPS) increased to $3.01 in the...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news
More News: Pharmaceuticals | Xgeva